Marlee Beauchamp
Medical · Las Vegas, NVNPI 1770222952
Payments from drug & device makers
Across 103 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$304
- Novo Nordisk$278
- Astellas Pharma US Inc$228
- GSK$203
- AbbVie$145
- Lilly USA, LLC$127
- plus $590 from 15 others
What the payments were for
- Food & beverage$1,875100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 17 | $304 |
| Novo Nordisk | 16 | $278 |
| Astellas Pharma US Inc | 12 | $228 |
| GSK | 9 | $203 |
| AbbVie | 8 | $145 |
| Lilly USA, LLC | 8 | $127 |
| Amgen | 6 | $116 |
| Otsuka America Pharmaceutical, Inc. | 6 | $102 |
| AstraZeneca | 5 | $76 |
| Lundbeck LLC | 3 | $57 |
| Boehringer Ingelheim | 2 | $50 |
| Exact Sciences | 2 | $32 |
| Sumitomo Pharma America, Inc. | 1 | $26 |
| Shield Therapeutics Inc | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
| Almatica Pharma LLC | 1 | $16 |
| Irhythm Technologies, Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
How this compares
$1,875 in reported general payments places this provider in the 65th percentile of 250 medical providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 54 | $93,593 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $35,118 |
| EliquisApixaban | 24 | $30,187 |
| RybelsusSemaglutide | 17 | $25,962 |
| JardianceEmpagliflozin | 21 | $25,417 |
| MyrbetriqMirabegron | 27 | $21,822 |
| JanuviaSitagliptin Phosphate | 19 | $11,691 |
| PaxlovidNirmatrelvir/Ritonavir | 12 | $1,429 |
| Testosterone Cypionate | 20 | $1,268 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 134 | $1,131 |
| SynthroidLevothyroxine Sodium | 17 | $1,122 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 47 | $1,001 |
| Gabapentin | 72 | $992 |
| Atorvastatin Calcium | 124 | $948 |
| Losartan Potassium | 106 | $925 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $278 | $119,55571 claims |
| GSKTrelegy Ellipta | $203 | $35,11829 claims |
| PfizerEliquis, Paxlovid | $304 | $31,61636 claims |
| Boehringer IngelheimJardiance | $50 | $25,41721 claims |
| Astellas Pharma US IncMyrbetriq | $228 | $21,82227 claims |
| AbbVieSynthroid | $145 | $1,12217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 250 medical providers in Nevada.
Other medical in Las Vegas
- John NotabartoloLas Vegas$284K
- Rachel BowersLas Vegas$29K
- Spencer MeierLas Vegas$24K
- Megan WieselLas Vegas$19K
- Tai PhamLas Vegas$16K
- Eric HilmesLas Vegas$15K
- Wardon OjedapoLas Vegas$12K
- Melchor GochiocoLas Vegas$11K
- Keesha KaplanLas Vegas$11K
- Adelbert WadsworthLas Vegas$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.